Icodextrin: an alternative peritoneal dialysis fluid

Bibliography

• Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States renal data system. J Am Soc Nephrol 2007;18:2644-8
   PubMed Web of Science ®Google Scholar
• Fenton SSA, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30(3):334-42
   PubMed Web of Science ®Google Scholar
• Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002;17(1):112-7
   PubMed Web of Science ®Google Scholar
• Brimble K, Walker M, Margetts P, et al. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006;17(9):2591-8
   PubMed Web of Science ®Google Scholar
• Davies S, Phillips L, Naish P, Russell G. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001;12(5):1046-51
   PubMed Web of Science ®Google Scholar
• Honda K, Nitta K, Horita S, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999;14(6):1541-9
   PubMed Web of Science ®Google Scholar
• Seo MJ, Oh SJ, Kim SI, et al. High glucose dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells. Perit Dial Int 2001;21:S35-40
   PubMed Web of Science ®Google Scholar
• Tjiong HL, Rietveld T, Wattimena JL, et al. Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2007;2(1):74-80
   PubMed Web of Science ®Google Scholar
• Chan TM, Yung S. Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int 2007;27:S87-93
   PubMed Web of Science ®Google Scholar
• Martikainen TA, Teppo AM, Gronhagen-Riska C, Ekstrand AV. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005;25(5):453-60
   PubMed Web of Science ®Google Scholar
• McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int 2007;71(6):486-90
   PubMed Web of Science ®Google Scholar
• Alsop R. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1993;14(Suppl 2):S5-12
   Google Scholar
• Moberly JB, Mujais S, Gehr T, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int 2002;62:S23-33
   Google Scholar
• Krediet RT. The physiology of peritoneal solute transport and ultrafiltration. In: Gokal RKR, Krediet R, Nolph K, editors, Textbook of peritoneal dialysis. Amsterdam: Kluwer Academic Publishers; 2000. p. 135-72
   Google Scholar
• Davies DS. Kinetics of icodextrin. Perit Dial Int 1993;14(Suppl 2):S45-50
   Google Scholar
• Mistry CD, Gokal R, Peers E, et al. A randomized multicenter clinical-trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994;46(2):496-503
   PubMed Web of Science ®Google Scholar
• HoDacPannekeet MM, Schouten N, Langendijk MJ, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996;50(3):979-86
   PubMed Web of Science ®Google Scholar
• Rippe B, Levin L. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000;57(6):2546-56
   PubMed Web of Science ®Google Scholar
• Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal-dialysis exchanges. Lancet 1987;2(8552):178-82
   PubMed Web of Science ®Google Scholar
• Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002;39(4):862-71
   PubMed Web of Science ®Google Scholar
• Delarue J, Maingourd C. Acute metabolic effects of dialysis fluids during CAPD. Am J Kidney Dis 2001;37(1):S103-7
   PubMed Web of Science ®Google Scholar
• Delarue J, Maingourd C, Lamisse F, et al. Glucose-oxidation after a peritoneal and an oral glucose-load in dialyzed patients. Kidney Int 1994;45(4):1147-52
   PubMed Web of Science ®Google Scholar
• Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int 2002;62:S62-1
   Web of Science ®Google Scholar
• Brulez HFH, van Guldener C, Donker AJM, ter Wee PM. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999;14(1):154-9
   PubMed Web of Science ®Google Scholar
• Fernstrom A, Hylander B, Moritz A, et al. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998;18(2):166-71
   PubMed Web of Science ®Google Scholar
• Woodrow G, Oldroyd B, Stables G, et al. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 2000;15(6):862-6
   PubMed Web of Science ®Google Scholar
• Johnson DW, Arndt M, O'Shea A, et al. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001;2:2
   PubMedGoogle Scholar
• Gradden CW, Ahmad R, Bell GM. Peritoneal dialysis: new developments and new problems. Diabet Med 2001;18(5):360-3
   PubMed Web of Science ®Google Scholar
• Lindholm B, Norbeck HE. Serum-lipids and lipoproteins during continuous ambulatory peritoneal-dialysis. Acta Med Scand 1986;220(2):143-51
   PubMed Web of Science ®Google Scholar
• Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998;13:45-9
   PubMed Web of Science ®Google Scholar
• Wheeler D. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996;54(Suppl 56):S41-6
   Web of Science ®Google Scholar
• Little J, Phillips L, Russell L, et al. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998;9(10):1931-9
   PubMed Web of Science ®Google Scholar
• Johansson AC, Samuelsson O, Attman PO, et al. Dyslipidemia in peritoneal dialysis – relation to dialytic variables. Perit Dial Int 2000;20(3):306-14
   PubMed Web of Science ®Google Scholar
• Bredie SJH, Bosch FH, Demacker PNM, et al. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001;21(3):275-81
   PubMed Web of Science ®Google Scholar
• Teta D, Maillard M, Halabi G, Burnier M. The leptin/adiponectin ratio: potential implications for peritoneal dialysis. Kidney Int 2008;73:S112-8
   Web of Science ®Google Scholar
• Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006;21(2):494-8
   PubMedGoogle Scholar
• Posthuma N, ter Wee PM, Donker AJM, et al. Serum disaccharides and osmolality in ccpd patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997;17(6):602-7
   PubMed Web of Science ®Google Scholar
• Katz MA. Hyperglycemia-induced hyponatremia – calculation of expected serum sodium depression. N Engl J Med 1973;289(16):843-4
   PubMed Web of Science ®Google Scholar
• Matz R. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 2000;108(2):180-1
   PubMed Web of Science ®Google Scholar
• Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106(4):399-403
   PubMed Web of Science ®Google Scholar
• Strand CL, Garcia H, Costales F. Hyponatremia in spontaneous hyperglycemia – correlation studies in 100 patients. Clin Chem 1987;33(10):1941-2
   PubMedGoogle Scholar
• Campbell HT, Fincher ME, Sklar AH. Severe hyponatremia without severe hypoosmolality following trans-urethral resection of the prostate (TURP) in end-stage renal-disease. Am J Kidney Dis 1988;12(2):152-5
   PubMed Web of Science ®Google Scholar
• Wolfson M, Piraino B, Hamburger RJ, Morton AR; Icodextrin Study G. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002;40(5):1055-65
   PubMed Web of Science ®Google Scholar
• 5th European Peritoneal Dialysis Meeting – EuRoPD (TM) – Brussels, Belgium – 2002 May 4 – 7 – Scientific Program – Abstracts. Perit Dial Int 2002;22(1):101-49
   Web of Science ®Google Scholar
• Kim SH, Goto M, Akaike T. Specific binding of glucose-derivatized polymers to the asialoglycoprotein receptor of mouse primary hepatocytes. J Biol Chem 2001;276(38):35312-9
   PubMed Web of Science ®Google Scholar
• Blom E, Ali MM, Mortensen B, Huseby NE. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta 1998;270(2):125-37
   PubMed Web of Science ®Google Scholar
• Janssen W, Harff G, Caers M, Schellekens A. Positive interference of icodextrin metabolites in some enzymatic glucose methods. Clin Chem 1998;44(11):2379-80
   PubMed Web of Science ®Google Scholar
• Wens R, Taminne M, Devriendt J, et al. A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer. Perit Dial Int 1998;18(6):603-9
   PubMed Web of Science ®Google Scholar
• Burke R, Hughes G, Moberly J. Lack of interference of icodextrin on creatinine measurements. Adv Perit Dial 1999;15:234-7
   PubMedGoogle Scholar
• Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001;2001(17):80-3
   Google Scholar
• Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005;16(2):546-54
   PubMed Web of Science ®Google Scholar
• Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14(9):2338-44
   PubMed Web of Science ®Google Scholar
• Wolfson M, Ogrinc F, Mujais S. Review of clinical trial experience with icodextrin. Kidney Int 2002;62:S46-52
   Web of Science ®Google Scholar
• Boer WH, Vos PF, Fieren M. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis. Perit Dial Int 2003;23(1):33-8
   PubMed Web of Science ®Google Scholar
• Martis L, Patel M, Giertych J, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005;365(9459):588-94
   PubMed Web of Science ®Google Scholar
• Gokal R, Mistry CD, Peers EM, et al. Peritonitis occurrence in a multicenter study of icodextrin and glucose in CAPD. Perit Dial Int 1995;15(6):226-30
   PubMed Web of Science ®Google Scholar
• Posthuma N, ter Wee PM, Donker AJM, et al. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999;19(4):334-42
   PubMed Web of Science ®Google Scholar
• Vychytil A, Remon C, Michel C, et al. Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study. Nephrol Dial Transplant advance access, published July 31 2008, doi: 10,1093/ndt./gfn 322
   PubMedGoogle Scholar
• Corporation BH. EXTRANEAL (icodextrin) Peritoneal Dialysis Solution. 2008 [cited]. Available from: http://www.baxter.com/products/renal/downloads/extraneal_pi.pdf
   Google Scholar
• Cooker LA, Holmes CJ, Hoff CM. Biocompatibility of icodextrin. Kidney Int 2002;62:S34-45
   Web of Science ®Google Scholar
• Cooker LA, Choo CG, Luneburg P, et al. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 1999;15:17-20
   PubMedGoogle Scholar
• Miyata T, Horie K, Yeda Y, et al. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000;58(1):425-35
   PubMed Web of Science ®Google Scholar
• Ueda Y, Miyata T, Goffin E, et al. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 2000;58(6):2518-24
   PubMed Web of Science ®Google Scholar
• Chung SH, Stenvinkel P, Bergstrom J, Lindholm B. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 2000;20:S57-67
   PubMed Web of Science ®Google Scholar
• Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Internat 2000;20:S48-56
   PubMedGoogle Scholar
• Wong TYH, Chan JCN, Szeto CC, et al. Clinical and biochemical characteristics of type 2 diabetic patients on continuous ambulatory peritoneal dialysis: relationships with insulin requirement. Am J Kidney Dis 1999;34(3):514-20
   PubMed Web of Science ®Google Scholar
• Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000;20(Suppl 4):S5-21
   PubMed Web of Science ®Google Scholar